Citations (172)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Mahdieh Mehrpouri, Majid Momeny & Davood Bashash. (2022) Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs. Journal of Receptors and Signal Transduction 42:1, pages 100-108.
Read now
Read now
Sandra E. Ghayad, Ghina Rammal, Omar Sarkis, Hussein Basma, Farah Ghamloush, Assil Fahs, Mia Karam, Mohamad Harajli, Wissam Rabeh, Joe E. Mouawad, Hassan Zalzali & Raya Saab. (2019) The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma. Cancer Biology & Therapy 20:3, pages 272-283.
Read now
Read now
MarianaS. Gerova & OgnyanI. Petrov. (2014) A Convenient Synthesis of the New Histone Deacetylase Inhibitor Scriptaid. Organic Preparations and Procedures International 46:1, pages 76-79.
Read now
Read now
Vincenzo Carafa, Marco Miceli, Lucia Altucci & Angela Nebbioso. (2013) Histone deacetylase inhibitors: a patent review (2009 – 2011). Expert Opinion on Therapeutic Patents 23:1, pages 1-17.
Read now
Read now
Samiha Mateen, Komal Raina, Anil K. Jain, Chapla Agarwal, Daniel Chan & Rajesh Agarwal. (2012) Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells. Epigenetics 7:10, pages 1161-1172.
Read now
Read now
Raghavendra Gowda, SubbaRao V. Madhunapantula, Dhimant Desai, Shantu Amin & Gavin P. Robertson. (2012) Selenium-containing histone deacetylase inhibitors for melanoma management. Cancer Biology & Therapy 13:9, pages 756-765.
Read now
Read now
Nozomu Tanji, Akira Ozawa, Tadahiko Kikugawa, Noriyoshi Miura, Toyokazu Sasaki, Kouji Azuma & Masayoshi Yokoyama. (2011) Potential of histone deacetylase inhibitors for bladder cancer treatment. Expert Review of Anticancer Therapy 11:6, pages 959-965.
Read now
Read now
Donald L Gardiner, Tina S Skinner-Adams, Christopher L Brown, Katherine T Andrews, Colin M Stack, James S McCarthy, John P Dalton & Katharine R Trenholme. (2009) Plasmodium falciparum: new molecular targets with potential for antimalarial drug development. Expert Review of Anti-infective Therapy 7:9, pages 1087-1098.
Read now
Read now
Francis Dumont, Anais Altmeyer & Pierre Bischoff. (2009) Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches. Expert Opinion on Therapeutic Patents 19:6, pages 775-799.
Read now
Read now
Dominik Sebastian Mestel, Marc Beyer, Markus Möbs, Matthias Steinhoff, Wolfram Sterry & Chalid Assaf. (2008) Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome. Expert Opinion on Biological Therapy 8:12, pages 1929-1939.
Read now
Read now
Brian R Keppler & Trevor K Archer. (2008) Chromatin-modifying enzymes as therapeutic targets – Part 1. Expert Opinion on Therapeutic Targets 12:10, pages 1301-1312.
Read now
Read now
Dominik Sebastian Mestel, Chalid Assaf, Matthias Steinhoff, Marc Beyer, Markus Moebs & Wolfram Sterry. (2008) Emerging drugs in cutaneous T cell lymphoma. Expert Opinion on Emerging Drugs 13:2, pages 345-361.
Read now
Read now
Walid Rasheed, Mark Bishton, Ricky W Johnstone & H Miles Prince. (2008) Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Review of Anticancer Therapy 8:3, pages 413-432.
Read now
Read now
Mark Bishton, Melita Kenealy, Ricky Johnstone, Walid Rasheed & H Miles Prince. (2007) Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Expert Review of Anticancer Therapy 7:10, pages 1439-1449.
Read now
Read now
Panagiotis A Konstantinopoulos, Michalis V Karamouzis & Athanasios G Papavassiliou. (2007) Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond. Expert Opinion on Investigational Drugs 16:5, pages 569-571.
Read now
Read now
Articles from other publishers (157)
Geetha Shanmugam, Krishnaveni Subramaniyam, Melvin George & Koustav Sarkar. (2023) HDAC inhibition regulates oxidative stress in CD4+Thelper cells of chronic obstructive pulmonary disease and non-small cell lung cancer patients via mitochondrial transcription factor a (mtTFA) modulating NF-κB/HIF1α axis. International Immunopharmacology 122, pages 110661.
Crossref
Crossref
Zhenzhen Wei, Yonghui Li, Faiza Ali, Ye Wang, Jisheng Liu, Zuoren Yang, Zhi Wang, Yadi Xing & Fuguang Li. (2022) Transcriptomic analysis reveals the key role of histone deacetylation via mediating different phytohormone signalings in fiber initiation of cotton. Cell & Bioscience 12:1.
Crossref
Crossref
Geetha Shanmugam, Jithin S. Sunny, Sudeshna Rakshit, Melvin George, K.V. Leela & Koustav Sarkar. (2022) Involvement of inflammatory cytokines and epigenetic modification of the mtTFA complex in T-helper cells of patients’ suffering from non-small cell lung cancer and chronic obstructive pulmonary disease. Molecular Immunology 151, pages 70-83.
Crossref
Crossref
Geetha Shanmugam, Sudeshna Rakshit & Koustav Sarkar. (2022) HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases. Translational Oncology 16, pages 101312.
Crossref
Crossref
Ye Yang, Baichun Hu, Yi Yang, Kaihua Gong, Huibin Wang, Qi Guo, Xinjie Tang, Yujuan Li & Jian Wang. (2021) Rational design of selective HDAC2 inhibitors for liver cancer treatment: computational insights into the selectivity mechanism through molecular dynamics simulations and QM/MM calculations. Physical Chemistry Chemical Physics 23:32, pages 17576-17590.
Crossref
Crossref
Dario Kringel, Sebastian Malkusch & Jörn Lötsch. (2021) Drugs and Epigenetic Molecular Functions. A Pharmacological Data Scientometric Analysis. International Journal of Molecular Sciences 22:14, pages 7250.
Crossref
Crossref
Ann‐Kathrin Rahm, Teresa Wieder, Dominik Gramlich, Mara Elena Müller, Maximilian N. Wunsch, Fadwa A. El Tahry, Tanja Heimberger, Steffi Sandke, Tanja Weis, Patrick Most, Hugo A. Katus, Dierk Thomas & Patrick Lugenbiel. (2021)
Differential regulation of K
Ca
2.1 (
KCNN1
) K
+
channel expression by histone deacetylases in atrial fibrillation with concomitant heart failure
. Physiological Reports 9:11.
Crossref
Crossref
Christoph Schröder, Rahul Khatri, Sebastian Friedrich Petry & Thomas Linn. (2020) Class I and II Histone Deacetylase Inhibitor LBH589 Promotes Endocrine
Differentiation in Bone Marrow Derived Human Mesenchymal Stem Cells and Suppresses
Uncontrolled Proliferation. Experimental and Clinical Endocrinology & Diabetes 129:05, pages 357-364.
Crossref
Crossref
Desislava V. Stanisheva, Gjorgji Atanasov, Margarita D. Aposstolova & Ognyan I. Petrov. (2021) Design, Synthesis and Biological Activity of New Hydroxamic Acids Containing 2-Imidazolylphenyl(oxy/thio)alkanoic Fragment. Current Bioactive Compounds 17:1, pages 59-66.
Crossref
Crossref
Ann-Kathrin Rahm, Teresa Wieder, Dominik Gramlich, Mara Elena Müller, Maximilian N. Wunsch, Fadwa A. El Tahry, Tanja Heimberger, Tanja Weis, Patrick Most, Hugo A. Katus, Dierk Thomas & Patrick Lugenbiel. (2021) HDAC2-dependent remodeling of KCa2.2 (KCNN2) and KCa2.3 (KCNN3) K+ channels in atrial fibrillation with concomitant heart failure. Life Sciences 266, pages 118892.
Crossref
Crossref
Dong Woo Kang, Won Chan Hwang, Yu Na Noh, Youra Kang, Younghoon Jang, Jung‐Ae Kim & Do Sik Min. (2020) Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma. Journal of Cellular Physiology 236:1, pages 549-560.
Crossref
Crossref
Francesca Cavallo, Flavia Troglio, Giovanni Fagà, Daniele Fancelli, Reinald Shyti, Sebastiano Trattaro, Matteo Zanella, Giuseppe D’Agostino, James M. Hughes, Maria Rosaria Cera, Maurizio Pasi, Michele Gabriele, Maddalena Lazzarin, Marija Mihailovich, Frank Kooy, Alessandro Rosa, Ciro Mercurio, Mario Varasi & Giuseppe Testa. (2020) High-throughput screening identifies histone deacetylase inhibitors that modulate GTF2I expression in 7q11.23 microduplication autism spectrum disorder patient-derived cortical neurons. Molecular Autism 11:1.
Crossref
Crossref
Denise Cantarelli Machado. (2020) Epigenomic profile and biological age. PAJAR - Pan American Journal of Aging Research 8:1, pages e37125.
Crossref
Crossref
Sugandha Singhal, Mallika Pathak, Paban K. Agrawala & Himanshu Ojha. (2020) Design and in silico screening of aryl allyl mercaptan analogs as potential histone deacetylases (HDAC) inhibitors. Heliyon 6:5, pages e03517.
Crossref
Crossref
Pargol Hashemi & Ivan Sadowski. (2019) Diversity of small molecule HIV‐1 latency reversing agents identified in low‐ and high‐throughput small molecule screens. Medicinal Research Reviews 40:3, pages 881-908.
Crossref
Crossref
Marion Wobser, Alexandra Weber, Amelie Glunz, Saskia Tauch, Kristina Seitz, Tobias Butelmann, Sonja Hesbacher, Matthias Goebeler, René Bartz, Hella Kohlhof, David Schrama & Roland Houben. (2019) Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells. Journal of Hematology & Oncology 12:1.
Crossref
Crossref
Maria Mrakovcic & Leopold F. Fröhlich. 2019. Genes and Cancer. Genes and Cancer.
Kajal Thapa, Savir Kumar, Anurag Sharma, Sandeep Arora, Amarjot Kaur Grewal & Thakur Gurjeet Singh. (2019) Histone Deacetylase Inhibitors As Potential Therapeutic Agents For Various Disorders. Journal of Pharmaceutical Technology, Research and Management 5:2, pages 235-253.
Crossref
Crossref
Maria Mrakovcic, Johannes Kleinheinz & Leopold F. Fröhlich. (2019) p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death. International Journal of Molecular Sciences 20:10, pages 2415.
Crossref
Crossref
Di Guo, Dun Hong, Peng Wang, Jiacheng Wang, Lihua Chen, Weibo Zhao, Liwei Zhang, Can Yao, Binxiang Chu, Shenao Chen, Zhiyan Li & Haixiao Chen. (2019) Histone deacetylase inhibitor CI-994 inhibits osteoclastogenesis via suppressing NF-κB and the downstream c-Fos/NFATc1 signaling pathways. European Journal of Pharmacology 848, pages 96-104.
Crossref
Crossref
Maria Mrakovcic, Lauren Bohner, Marcel Hanisch & Leopold F. Fröhlich. (2018) Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53. International Journal of Molecular Sciences 19:12, pages 3952.
Crossref
Crossref
Xian Zhang, Dakshesh Patel, Qin Xu & Richard Veenstra. (2018) Differences in Functional Expression of Connexin43 and NaV1.5 by Pan- and Class-Selective Histone Deacetylase Inhibition in Heart. International Journal of Molecular Sciences 19:8, pages 2288.
Crossref
Crossref
Jae-Wook Lee, Dong Hee Yang, Sojin Park, Hae-Kyoung Han, Jong-Wan Park, Bo Yeon Kim, Sung Hee Um & Eun-Yi Moon. (2017) Trichostatin A resistance is facilitated by HIF-1α acetylation in HeLa human cervical cancer cells under normoxic conditions. Oncotarget 9:2, pages 2035-2049.
Crossref
Crossref
Shabir Ahmad Ganai, Ehsaan Abdullah, Romana Rashid & Mohammad Altaf. (2017) Combinatorial In Silico Strategy towards Identifying Potential Hotspots during Inhibition of Structurally Identical HDAC1 and HDAC2 Enzymes for Effective Chemotherapy against Neurological Disorders. Frontiers in Molecular Neuroscience 10.
Crossref
Crossref
Michael J. Topper, Michelle Vaz, Katherine B. Chiappinelli, Christina E. DeStefano Shields, Noushin Niknafs, Ray-Whay Chiu Yen, Alyssa Wenzel, Jessica Hicks, Matthew Ballew, Meredith Stone, Phuoc T. Tran, Cynthia A. Zahnow, Matthew D. Hellmann, Valsamo Anagnostou, Pamela L. Strissel, Reiner Strick, Victor E. Velculescu & Stephen B. Baylin. (2017) Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. Cell 171:6, pages 1284-1300.e21.
Crossref
Crossref
Maria Mrakovcic, Johannes Kleinheinz & Leopold Fröhlich. (2017) Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53. International Journal of Molecular Sciences 18:9, pages 1883.
Crossref
Crossref
Tomas Eckschlager, Johana Plch, Marie Stiborova & Jan Hrabeta. (2017) Histone Deacetylase Inhibitors as Anticancer Drugs. International Journal of Molecular Sciences 18:7, pages 1414.
Crossref
Crossref
Aliasghar Rahimian & Ali Mellati. (2017) The Effect of Histone Hyperacetylation on Viability of Basal-Like Breast Cancer Cells MDA-MB-231. Razavi International Journal of Medicine 5:2.
Crossref
Crossref
Ran Li & Ye-Hua Gan. (2017) Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Iβ Expression. International Journal of Molecular Sciences 18:5, pages 1010.
Crossref
Crossref
Mudassier Ahmad, Mushtaq A. Aga, Javeed Ahmad Bhat, Brijesh Kumar, Abdul Rouf, Neena Capalash, Mubashir Javeed Mintoo, Ashok Kumar, Priya Mahajan, Dilip Manikrao Mondhe, Amit Nargotra, Parduman Raj Sharma, Mohmmad Afzal Zargar, Ram A. Vishwakarma, Bhahwal Ali Shah, Subhash Chandra Taneja & Abid Hamid. (2017)
Exploring Derivatives of Quinazoline Alkaloid
l
-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors
. Journal of Medicinal Chemistry 60:8, pages 3484-3497.
Crossref
Crossref
Dong Hoon Lee, Hyun-Wook Ryu, Hye-Rim Won & So Hee Kwon. (2017) Advances in epigenetic glioblastoma therapy. Oncotarget 8:11, pages 18577-18589.
Crossref
Crossref
Xiaoli Ma, Jiandong Wang, Jia Liu, Qingqing Mo, Xiyun Yan, Ding Ma & Hua Duan. (2017) Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells. Oncology Letters 13:3, pages 1681-1687.
Crossref
Crossref
Thomas Mikeska & Alexander Dobrovic. 2017. The Molecular Basis of Human Cancer. The Molecular Basis of Human Cancer
83
102
.
Kol Jia Yong, Ailing Li, Wen-Bin Ou, Clarice Kit Yee Hong, Wenxiu Zhao, Fei Wang, Hiro Tatetsu, Benedict Yan, Lihua Qi, Jonathan A. Fletcher, Henry Yang, Ross Soo, Daniel G. Tenen & Li Chai. (2016) Targeting SALL4 by entinostat in lung cancer. Oncotarget 7:46, pages 75425-75440.
Crossref
Crossref
Qin Xu, Dakshesh Patel, Xian Zhang & Richard D. Veenstra. (2016)
Changes in cardiac Na
v
1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors
. American Journal of Physiology-Heart and Circulatory Physiology 311:5, pages H1139-H1149.
Crossref
Crossref
Min Yan, Yuan-min Qian, Cai-feng Yue, Zi-feng Wang, Bi-cheng Wang, Wei Zhang, Fei-meng Zheng & Quentin Liu. (2016) Inhibition of histone deacetylases induces formation of multipolar spindles and subsequent p53-dependent apoptosis in nasopharyngeal carcinoma cells. Oncotarget 7:28, pages 44171-44184.
Crossref
Crossref
H M Tang, K T Kuay, P F Koh, M Asad, T Z Tan, V Y Chung, S C Lee, J P Thiery & RY-J Huang. (2016) An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers. Cell Death Discovery 2:1.
Crossref
Crossref
Rikke D. Rasmussen, Madhavsai K. Gajjar, Kamilla E. Jensen & Petra Hamerlik. (2016) Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma. Molecular Oncology 10:5, pages 751-763.
Crossref
Crossref
Haiping Zhao, Ziping Han, Xunming Ji & Yumin Luo. (2016) Epigenetic Regulation of Oxidative Stress in Ischemic Stroke. Aging and disease 7:3, pages 295.
Crossref
Crossref
Yong Ling, Chenjun Xu, Lin Luo, Jingyi Cao, Jiao Feng, Yu Xue, Qing Zhu, Caoyun Ju, Fengzhi Li, Yihua Zhang, Yanan Zhang & Xiang Ling. (2015) Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway. Journal of Medicinal Chemistry 58:23, pages 9214-9227.
Crossref
Crossref
Min-Wu Chao, Mei-Jung Lai, Jing-Ping Liou, Ya-Ling Chang, Jing-Chi Wang, Shiow-Lin Pan & Che-Ming Teng. (2015) The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. Journal of Hematology & Oncology 8:1.
Crossref
Crossref
Stéphanie Vandekerckhove & Matthias D’hooghe. (2015) Quinoline-based antimalarial hybrid compounds. Bioorganic & Medicinal Chemistry 23:16, pages 5098-5119.
Crossref
Crossref
Somprasong Khaopha, Sanun Jogloy, Aran Patanothai & Thanaset Senawong. (2015) Histone Deacetylase Inhibitory Activity of Peanut Testa Extracts against Human Cancer Cell Lines. Journal of Food Biochemistry 39:3, pages 263-273.
Crossref
Crossref
Jingwei Zhou, Min Li, Nanhao Chen, Shenglong Wang, Hai-Bin Luo, Yingkai Zhang & Ruibo Wu. (2015) Computational Design of a Time-Dependent Histone Deacetylase 2 Selective Inhibitor. ACS Chemical Biology 10:3, pages 687-692.
Crossref
Crossref
Zhen-Feng Hao, You-Ming Su, Cong-min Wang & Rong-Ya Yang. (2014) Activating transcription factor 3 interferes with p21 activation in histone deacetylase inhibitor-induced growth inhibition of epidermoid carcinoma cells. Tumor Biology 36:3, pages 1471-1476.
Crossref
Crossref
XIAOLI MA, HUA DUAN, JIA LIU, QINGQING MO, CHENGJUAN SUN, DING MA & JIANDONG WANG. (2015) Effect of LIV1 on the sensitivity of ovarian cancer cells to trichostatin A. Oncology Reports 33:2, pages 893-898.
Crossref
Crossref
Hua Zhang, Xufeng Dai, Yan Qi, Ying He, Wei Du & Ji-jing Pang. (2015) Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives. Journal of Ophthalmology 2015, pages 1-9.
Crossref
Crossref
Nicola Chessum, Keith Jones, Elisa Pasqua & Michael Tucker. 2015.
1
63
.
Sadeghi Zohre, Nejati-Koshki Kazem, Akbarzadeh Abolfazl, Rahmati-Yamchi Mohammad, Movassaghpour Aliakbar, Alizadeh Effat, Davoudi Zahra, Dariushnejad Hassan & Zarghami Nosratollah. (2014) Trichostatin A-induced Apoptosis is Mediated by Kr?ppel-like Factor 4 in Ovarian and Lung Cancer. Asian Pacific Journal of Cancer Prevention 15:16, pages 6581-6586.
Crossref
Crossref
Ya-Ju Hsieh, Luen Hwu, Yi-Chieh Chen, Chien-Chih Ke, Fu-Du Chen, Hsin-Ell Wang, Kang-Ping Lin, Hsin-Hsien Yeh, Chi-Wei Chang & Ren-Shyan Liu. (2014) P21-Driven Multifusion Gene System for Evaluating the Efficacy of Histone Deacetylase Inhibitors by In Vivo Molecular Imaging and for Transcription Targeting Therapy of Cancer Mediated by Histone Deacetylase Inhibitor. Journal of Nuclear Medicine 55:4, pages 678-685.
Crossref
Crossref
Isabelle Tranoy-Opalinski, Thibaut Legigan, Romain Barat, Jonathan Clarhaut, Mikaël Thomas, Brigitte Renoux & Sébastien Papot. (2014) β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: An update. European Journal of Medicinal Chemistry 74, pages 302-313.
Crossref
Crossref
Charles S. Ward. (2014) Autism’s cancer connection: The anti-proliferation hypothesis and why it may matter. Medical Hypotheses 82:1, pages 26-35.
Crossref
Crossref
Thanaset Senawong, Suwatchai Misuna, Somprasong Khaopha, Suporn Nuchadomrong, Prasan Sawatsitang, Chanokbhorn Phaosiri, Arpa Surapaitoon & Banchob Sripa. (2013) Histone deacetylase (HDAC) inhibitory and antiproliferative activities of phenolic-rich extracts derived from the rhizome of Hydnophytum formicarum Jack.: sinapinic acid acts as HDAC inhibitor. BMC Complementary and Alternative Medicine 13:1.
Crossref
Crossref
Kornelius Kerl, David Ries, Rebecca Unland, Christiane Borchert, Natalia Moreno, Martin Hasselblatt, Heribert Jürgens, Marcel Kool, Dennis Görlich, Maria Eveslage, Manfred Jung, Michael Meisterernst & Michael Frühwald. (2013) The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells. BMC Cancer 13:1.
Crossref
Crossref
Andrea Newbold, Geoffrey M. Matthews, Michael Bots, Leonie A. Cluse, Christopher J.P. Clarke, Kellie-Marie Banks, Carleen Cullinane, Jessica E. Bolden, Ailsa J. Christiansen, Ross A. Dickins, Claudia Miccolo, Susanna Chiocca, Astrid M. Kral, Nicole D. Ozerova, Thomas A. Miller, Joey L. Methot, Victoria M. Richon, J. Paul Secrist, Saverio Minucci & Ricky W. Johnstone. (2013) Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities. Molecular Cancer Therapeutics 12:12, pages 2709-2721.
Crossref
Crossref
Ji Hoon Jung, Soo-Jin Jeong, Ji-Hyun Kim, Sung-Ki Jung, Deok-Beom Jung, Duckgu Lee, Eun Jung Sohn, Miyong Yun, Hyo-Jung Lee, Hyo-Jeong Lee & Sung-Hoon Kim. (2013) Inactivation of HDAC3 and STAT3 is Critically Involved in 1-Stearoyl-sn-Glycero-3-Phosphocholine-Induced Apoptosis in Chronic Myelogenous Leukemia K562 Cells. Cell Biochemistry and Biophysics 67:3, pages 1379-1389.
Crossref
Crossref
YOUNG-JOO JEON, SEON MI KO, JIN HYOUNG CHO, JUNG-IL CHAE & JUNG-HYUN SHIM. (2013) The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma. International Journal of Molecular Medicine 32:4, pages 860-866.
Crossref
Crossref
Shauna N. Vasilatos, Tiffany A. Katz, Steffi Oesterreich, Yong Wan, Nancy E. Davidson & Yi Huang. (2013) Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis 34:6, pages 1196-1207.
Crossref
Crossref
Chengyue Zhang, Zheng-Yuan Su, Tin Oo Khor, Limin Shu & Ah-Ng Tony Kong. (2013) Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation. Biochemical Pharmacology 85:9, pages 1398-1404.
Crossref
Crossref
Reecha D. Shah, Jayashree C. Jagtap, S. Mruthyunjaya, Ganesh V. Shelke, Radha Pujari, Gowry Das & Padma Shastry. (2013) Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition. Journal of Cellular Biochemistry 114:4, pages 854-863.
Crossref
Crossref
Anna Laurenzana, Manjola Balliu, Cristina Cellai, Maria Novella Romanelli & Francesco Paoletti. (2013) Effectiveness of the Histone Deacetylase Inhibitor (S)-2 against LNCaP and PC3 Human Prostate Cancer Cells. PLoS ONE 8:3, pages e58267.
Crossref
Crossref
Guan-Min Jiang, Hong-Sheng Wang, Fan Zhang, Kun-Shui Zhang, Zong-Cai Liu, Rui Fang, Hao Wang, Shao-Hui Cai & Jun Du. (2013) Histone deacetylase inhibitor induction of epithelial?mesenchymal transitions via up-regulation of Snail facilitates cancer progression. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1833:3, pages 663-671.
Crossref
Crossref
Tianzhu Qiu, Li Zhou, Wei ZhuTongshan Wang, Jian Wang, Yongqian Shu & Ping Liu. (2013) Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. Future Oncology 9:2, pages 255-269.
Crossref
Crossref
Angela Nebbioso, Vincenzo Carafa, Rosaria Benedetti & Lucia Altucci. (2012) Trials with ‘epigenetic’ drugs: An update. Molecular Oncology 6:6, pages 657-682.
Crossref
Crossref
Zacharoula Konsoula & Frank A. Barile. (2012) Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders. Journal of Pharmacological and Toxicological Methods 66:3, pages 215-220.
Crossref
Crossref
Mudassier AhmadAbid HamidAashiq HussainRabiya MajeedYasrib QurishiJaveed Ahmad BhatRauf Ahmad NajarAsif Khurshid QaziMohmmad Afzal ZargarShashank Kumar SinghAjit Kumar Saxena. (2012) Understanding Histone Deacetylases in the Cancer Development and Treatment: An Epigenetic Perspective of Cancer Chemotherapy. DNA and Cell Biology 31:S1, pages S-62-S-71.
Crossref
Crossref
Laura Gatti, Valentina Benedetti, Michelandrea De Cesare, Elisabetta Corna, Raffaella Cincinelli, Nadia Zaffaroni, Franco Zunino & Paola Perego. (2012) Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells. Journal of Inorganic Biochemistry 113, pages 94-101.
Crossref
Crossref
Don S. Dizon, Lars Damstrup, Neil J. Finkler, Ulrik Lassen, Paul Celano, Ros Glasspool, Elizabeth Crowley, Henri S. Lichenstein, Poul Knoblach & Richard T. Penson. (2012) Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer. International Journal of Gynecological Cancer 22:6, pages 979-986.
Crossref
Crossref
Don S. Dizon, John A. Blessing, Richard T. Penson, Richard D. Drake, Joan L. Walker, Carolyn M. Johnston, Paul A. DiSilvestro & Amanda Nickles Fader. (2012) A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study. Gynecologic Oncology 125:2, pages 367-371.
Crossref
Crossref
Berkley E Gryder, Quaovi H Sodji & Adegboyega K Oyelere. (2012) Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Medicinal Chemistry 4:4, pages 505-524.
Crossref
Crossref
Bhawana Singh, Sivaraman Boopathy, Kumaravel Somasundaram & Siva Umapathy. (2012) Fourier transform infrared microspectroscopy identifies protein propionylation in histone deacetylase inhibitor treated glioma cells. Journal of Biophotonics 5:3, pages 230-239.
Crossref
Crossref
Michael J. Monument, Stephen L. Lessnick, Joshua D. Schiffman & Rl. Tx. Randall. (2012) Microsatellite Instability in Sarcoma: Fact or Fiction?. ISRN Oncology 2012, pages 1-9.
Crossref
Crossref
Katherine T Andrews, Ashraful Haque & Malcolm K Jones. (2011) HDAC inhibitors in parasitic diseases. Immunology & Cell Biology 90:1, pages 66-77.
Crossref
Crossref
Rentian Feng & Suzanne Lentzsch. 2012. Oxidative Stress in Cancer Biology and Therapy. Oxidative Stress in Cancer Biology and Therapy
219
231
.
Zheng-Yuan Su, Limin Shu, Tin Oo Khor, Jong Hun Lee, Francisco Fuentes & Ah-Ng Tony Kong. 2013. Natural Products in Cancer Prevention and Therapy. Natural Products in Cancer Prevention and Therapy
133
162
.
Eleni Pontiki & Dimitra Hadjipavlou-Litina. (2012) Histone deacetylase inhibitors (HDACIs). Structure-activity relationships: history and new QSAR perspectives. Medicinal Research Reviews 32:1, pages 1-165.
Crossref
Crossref
Sundarapandian Thangapandian, Shalini John, Yuno Lee, Songmi Kim & Keun Woo Lee. (2011) Dynamic Structure-Based Pharmacophore Model Development: A New and Effective Addition in the Histone Deacetylase 8 (HDAC8) Inhibitor Discovery. International Journal of Molecular Sciences 12:12, pages 9440-9462.
Crossref
Crossref
Ruman Rahman & Richard Grundy. (2011) Histone deacetylase inhibition as an anticancer telomerase‐targeting strategy. International Journal of Cancer 129:12, pages 2765-2774.
Crossref
Crossref
Mi-Sook Kim. (2011) Future Cancer Therapy with Molecularly Targeted Therapeutics: Challenges and Strategies. Biomolecules and Therapeutics 19:4, pages 371-389.
Crossref
Crossref
Miglena Koprinarova, Peter Botev & George Russev. (2011) Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination. DNA Repair 10:9, pages 970-977.
Crossref
Crossref
M. M. Singh, C. A. Manton, K. P. Bhat, W.-W. Tsai, K. Aldape, M. C. Barton & J. Chandra. (2011) Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro-Oncology 13:8, pages 894-903.
Crossref
Crossref
Markus Weiller, Timo Weiland, Georg Dünstl, Ulrike Sack, Gerald Künstle & Albrecht Wendel. (2011) Differential immunotoxicity of histone deacetylase inhibitors on malignant and naïve hepatocytes. Experimental and Toxicologic Pathology 63:5, pages 511-517.
Crossref
Crossref
Eun-Ra Jang, Yun Jeong Kim, Soon Chul Myung, Wonyong Kim & Chung Soo Lee. (2011) Different effect of protein kinase B/Akt and extracellular signal-regulated kinase inhibition on trichostatin A-induced apoptosis in epithelial ovarian carcinoma cell lines. Molecular and Cellular Biochemistry 353:1-2, pages 1-11.
Crossref
Crossref
Yen-Ying Ma, Hao Lin, Jau-Sung Moh, Kuang-Den Chen, I-Wen Wang, Yu-Che Ou, Ying-Shu You & Chia-Chi Lung. (2011) Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells. Taiwanese Journal of Obstetrics and Gynecology 50:2, pages 165-171.
Crossref
Crossref
Ben P. Martin, Ailsa J. Frew, Michael Bots, Stephen Fox, Fenella Long, Kazuyoshi Takeda, Hideo Yagita, Peter Atadja, Mark J. Smyth & Ricky W. Johnstone. (2011) Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. International Journal of Cancer 128:11, pages 2735-2747.
Crossref
Crossref
John Spencer, Jahangir Amin, Minghua Wang, Graham Packham, Sharifah S. Syed Alwi, Graham J. Tizzard, Simon J. Coles, Ronald M. Paranal, James E. Bradner & Tom D. Heightman. (2011) Synthesis and Biological Evaluation of JAHAs: Ferrocene-Based Histone Deacetylase Inhibitors. ACS Medicinal Chemistry Letters 2:5, pages 358-362.
Crossref
Crossref
Zacharoula Konsoula, Hong Cao, Alfredo Velena & Mira Jung. (2011) Adamantanyl-Histone Deacetylase Inhibitor H6CAHA Exhibits Favorable Pharmacokinetics and Augments Prostate Cancer Radiation Sensitivity. International Journal of Radiation Oncology*Biology*Physics 79:5, pages 1541-1548.
Crossref
Crossref
Beom Soo Shin, Jürgen B. Bulitta, Deok Ki Hong, Hye Youn Kim, Min Ki Kim, Yohan Choi, Jong Bong Lee, Sang Wook Hwang, Mann Hyung Lee & Sun Dong Yoo. (2011) Population Pharmacokinetics of a Novel Histone Deacetylase Inhibitor, Cyclo{(2S)-2-Amino-8-[(Aminocarbonyl)Hydrazono] Decanoyl-1-<i>L</i>-Tryptophyl-<i>L</i>-Isoleucyl-(2R)-2-Piperidinecarbonyl} (SD-2007), and Its Metabolic Conversion to Apicidin after Intravenous Injection and Oral Administration in Rats. Chemotherapy 57:3, pages 259-267.
Crossref
Crossref
Mario Federico & Luigi Bagella. (2011) Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors. Journal of Biomedicine and Biotechnology 2011, pages 1-12.
Crossref
Crossref
Eun-Kyung Park, Eun-Hyung Jeon, In-Ho Kim & Seon-Yang Park. (2010) Recovery of Genes Epigenetically Altered by the Histone Deacetylase Inhibitor Scriptaid and Demethylating Agent 5-Azacytidine in Human Leukemia Cells. Genomics & Informatics 8:4, pages 185-193.
Crossref
Crossref
Patrick Imesch, Daniel Fink & André Fedier. (2010) Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells. Fertility and Sterility 94:7, pages 2838-2842.
Crossref
Crossref
Chung Soo Lee, Jae Chon Yang, Yun Jeong Kim, Eun-Ra Jang, Wonyong Kim & Soon Chul Myung. (2010) 18β-Glycyrrhetinic acid potentiates apoptotic effect of trichostatin A on human epithelial ovarian carcinoma cell lines. European Journal of Pharmacology 649:1-3, pages 354-361.
Crossref
Crossref
Sridurga Mithraprabhu, George Grigoriadis, Tiffany Khong & Andrew Spencer. (2010) Deactylase inhibition in myeloproliferative neoplasms. Investigational New Drugs 28:S1, pages 50-57.
Crossref
Crossref
Enrique M. Ocio & Jesús F. San Miguel. (2010) The DAC system and associations with multiple myeloma. Investigational New Drugs 28:S1, pages 28-35.
Crossref
Crossref
Xiaoli Ma, Jia Liu, Jiang Wu, Xiyun Yan, Peng Wu, Yong Liu, Shuang Li, Yuan Tian, Yang Cao, Gang Chen, Li Meng, Gang Xu, Shixuan Wang, Yunping Lu, Ding Ma & Jianfeng Zhou. (2010) Synergistic Killing Effect between Vorinostat and Target of CD146 in Malignant Cells. Clinical Cancer Research 16:21, pages 5165-5176.
Crossref
Crossref
Amit Deorukhkar, Shujun Shentu, Hee Chul Park, Parmeswaran Diagaradjane, Vinay Puduvalli, Bharat Aggarwal, Sushovan Guha & Sunil Krishnan. (2010) Inhibition of Radiation-Induced DNA Repair and Prosurvival Pathways Contributes to Vorinostat-Mediated Radiosensitization of Pancreatic Cancer Cells. Pancreas 39:8, pages 1277-1283.
Crossref
Crossref
Jan C. Purrucker & Ulrich Mahlknecht. (2010) Targeting the epigenome: effects of epigenetic treatment strategies on genomic stability in healthy human cells. Clinical Epigenetics 1:1-2, pages 45-54.
Crossref
Crossref
John J. Wright. (2010) Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy. Clinical Cancer Research 16:16, pages 4094-4104.
Crossref
Crossref
Moshe Szyf. (2009) Epigenetic Therapeutics in Autoimmune Disease. Clinical Reviews in Allergy & Immunology 39:1, pages 62-77.
Crossref
Crossref
Ciro Mercurio, Saverio Minucci & Pier Giuseppe Pelicci. (2010) Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacological Research 62:1, pages 18-34.
Crossref
Crossref
Masaki Kitazono, Hiroyuki Shinchi, Sumiya Ishigami, Shinichi Ueno & Shoji Natsugoe. (2010) Effects of a histone deacetylase inhibitor, sodium butyrate, on 53-kDa protein expression and sensitivity to anticancer drugs of pancreatic cancer cells. Current Therapeutic Research 71:3, pages 162-172.
Crossref
Crossref
Eric D. de Groh, Lisa M. Swanhart, Chiara Cianciolo Cosentino, Rachel L. Jackson, Weixiang Dai, Carolyn A. Kitchens, Billy W. Day, Thomas E. Smithgall & Neil A. Hukriede. (2010) Inhibition of Histone Deacetylase Expands the Renal Progenitor Cell Population. Journal of the American Society of Nephrology 21:5, pages 794-802.
Crossref
Crossref
Chung Soo Lee, Eun-Ra Jang, Yun Jeong Kim, Soon Chul Myung & Wonyong Kim. (2009) Casein kinase 2 inhibition differentially modulates apoptotic effect of trichostatin A against epithelial ovarian carcinoma cell lines. Molecular and Cellular Biochemistry 338:1-2, pages 157-166.
Crossref
Crossref
Pritika Narayan & Mike Dragunow. (2010) Pharmacology of epigenetics in brain disorders. British Journal of Pharmacology 159:2, pages 285-303.
Crossref
Crossref
John Patrick Alao. 2009. Checkpoint Controls and Targets in Cancer Therapy. Checkpoint Controls and Targets in Cancer Therapy
123
153
.
Enrique Espinosa & César Gómez Raposo. 2010. Macromolecular Anticancer Therapeutics. Macromolecular Anticancer Therapeutics
3
35
.
Paola Galletti, Arianna Quintavalla, Caterina Ventrici, Giuseppe Giannini, Walter Cabri, Sergio Penco, Grazia Gallo, Silvia Vincenti & Daria Giacomini. (2009) Azetidinones as Zinc-Binding Groups to Design Selective HDAC8 Inhibitors. ChemMedChem 4:12, pages 1991-2001.
Crossref
Crossref
H. Miles PrinceSean Whittaker & Richard T. Hoppe. (2009) How I treat mycosis fungoides and Sézary syndrome. Blood 114:20, pages 4337-4353.
Crossref
Crossref
Xiaoping Huang, Lizhi Gao, Shuiliang Wang, Choon-Kee Lee, Peter Ordentlich & Bolin Liu. (2009) HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression. Cancer Research 69:21, pages 8403-8411.
Crossref
Crossref
D.S. Mestel, M. Beyer, M. Steinhoff & W. Sterry. (2009) Treatment of Cutaneous Lymphomas: Today and Tomorrow. Actas Dermo-Sifiliográficas 100, pages 18-32.
Crossref
Crossref
John P. Alao, Jeanette Olesch & Per Sunnerhagen. (2009) Inhibition of type I histone deacetylase increases resistance of checkpoint-deficient cells to genotoxic agents through mitotic delay. Molecular Cancer Therapeutics 8:9, pages 2606-2615.
Crossref
Crossref
Yutaka Fujiwara, Noboru Yamamoto, Yasuhide Yamada, Kazuhiko Yamada, Tetsuya Otsuki, Shinichi Kanazu, Takashi Iwasa, James S. Hardwick & Tomohide Tamura. (2009) Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Science 100:9, pages 1728-1734.
Crossref
Crossref
Hong-Jun Pi, Hua Liu, Wenting Du & Wei-Ping Deng. (2009) The facile synthesis of benzothiazolylideneacetates and 1,4-benzothiazines through a highly controllable oxidation of benzothiazolylacetates. Tetrahedron Letters 50:31, pages 4529-4531.
Crossref
Crossref
Nicolas Batty, Gabriel G. Malouf & Jean Pierre J. Issa. (2009) Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Letters 280:2, pages 192-200.
Crossref
Crossref
Ailsa J. Frew, Ricky W. Johnstone & Jessica E. Bolden. (2009) Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Letters 280:2, pages 125-133.
Crossref
Crossref
Georgia Melagraki, Antreas Afantitis, Haralambos Sarimveis, Panayiotis A. Koutentis, George Kollias & Olga Igglessi-Markopoulou. (2009) Predictive QSAR workflow for the in silico identification and screening of novel HDAC inhibitors. Molecular Diversity 13:3, pages 301-311.
Crossref
Crossref
Leigh EllisMichael BotsRalph K. LindemannJessica E. BoldenAndrea NewboldLeonie A. CluseClare L. ScottAndreas StrasserPeter AtadjaScott W. Lowe & Ricky W. Johnstone. (2009) The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 114:2, pages 380-393.
Crossref
Crossref
T Neff & S A Armstrong. (2009) Chromatin maps, histone modifications and leukemia. Leukemia 23:7, pages 1243-1251.
Crossref
Crossref
Cédric Charrier, Joëlle Roche, Jean-Pierre Gesson & Philippe Bertrand. (2009) Biological activities of substituted trichostatic acid derivatives. Journal of Chemical Sciences 121:4, pages 471-479.
Crossref
Crossref
P.A. Marks & W.‐S. Xu. (2009) Histone deacetylase inhibitors: Potential in cancer therapy. Journal of Cellular Biochemistry 107:4, pages 600-608.
Crossref
Crossref
Michael Bots & Ricky W. Johnstone. (2009) Rational Combinations Using HDAC Inhibitors. Clinical Cancer Research 15:12, pages 3970-3977.
Crossref
Crossref
Yasuaki Dewa, Jihei Nishimura, Meilan Jin, Masaomi Kawai, Yukie Saegusa, Tomoaki Harada, Makoto Shibutani & Kunitoshi Mitsumori. (2009) Molecular Expression Analysis of β-Naphthoflavone-induced Hepatocellular Tumors in Rats. Toxicologic Pathology 37:4, pages 446-455.
Crossref
Crossref
Deepa Sampath, George A. Calin, Vinay K. PuduvalliGopal GopisettyCristian Taccioli, Chang-Gong Liu, Brett Ewald, Chaomei Liu, Michael J. Keating & William Plunkett. (2009) Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 113:16, pages 3744-3753.
Crossref
Crossref
Fabian Vandermeers, Pascale Hubert, Philippe Delvenne, Céline Mascaux, Bogdan Grigoriu, Arsène Burny, Arnaud Scherpereel & Luc Willems. (2009) Valproate, in Combination with Pemetrexed and Cisplatin, Provides Additional Efficacy to the Treatment of Malignant Mesothelioma. Clinical Cancer Research 15:8, pages 2818-2828.
Crossref
Crossref
Adil I. Daud, Jana Dawson, Ronald C. DeConti, Elona Bicaku, Douglas Marchion, Sem Bastien, Frederick A. HausheerIIIIII, Richard Lush, Anthony Neuger, Daniel M. Sullivan & Pamela N. Munster. (2009) Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial. Clinical Cancer Research 15:7, pages 2479-2487.
Crossref
Crossref
Giuseppe Giannini, Mauro Marzi, Riccardo Pezzi, Tiziana Brunetti, Gianfranco Battistuzzi, Maria Di Marzo, Walter Cabri, Loredana Vesci & Claudio Pisano. (2009) N-Hydroxy-(4-oxime)-cinnamide: A versatile scaffold for the synthesis of novel histone deacetilase (HDAC) inhibitors. Bioorganic & Medicinal Chemistry Letters 19:8, pages 2346-2349.
Crossref
Crossref
Moshe Szyf. (2009) Epigenetics, DNA Methylation, and Chromatin Modifying Drugs. Annual Review of Pharmacology and Toxicology 49:1, pages 243-263.
Crossref
Crossref
Grégory Eot-Houllier, Géraldine Fulcrand, Laura Magnaghi-Jaulin & Christian Jaulin. (2009) Histone deacetylase inhibitors and genomic instability. Cancer Letters 274:2, pages 169-176.
Crossref
Crossref
D Mottet, S Pirotte, V Lamour, M Hagedorn, S Javerzat, A Bikfalvi, A Bellahcène, E Verdin & V Castronovo. (2008) HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 28:2, pages 243-256.
Crossref
Crossref
Lyse A. Norian, Tamara A. Kucaba, James K. Earel, Tina Knutson, Rebecca L. vanOosten & Thomas S. Griffith. (2009) Synergistic Induction of Apoptosis in Primary B-CLL Cells after Treatment with Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Histone Deacetylase Inhibitors. Journal of Oncology 2009, pages 1-8.
Crossref
Crossref
Amel Baya Bouzar, Mathieu Boxus, Julien Defoiche, Guy Berchem, Derek Macallan, Ruth Pettengell, Fenella Willis, Arsène Burny, Laurence Lagneaux, Dominique Bron, Bernard Chatelain, Christian Chatelain & Luc Willems. (2009) Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. British Journal of Haematology 144:1, pages 41-52.
Crossref
Crossref
A Rocca, S Minucci, G Tosti, D Croci, F Contegno, M Ballarini, F Nolè, E Munzone, A Salmaggi, A Goldhirsch, P G Pelicci & A Testori. (2009) A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. British Journal of Cancer 100:1, pages 28-36.
Crossref
Crossref
Eun Joo Noh, Dae-Sik Lim, Gajin Jeong & Jong-Soo Lee. (2009) An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner. Biochemical and Biophysical Research Communications 378:3, pages 326-331.
Crossref
Crossref
Isabelle Jariel-Encontre, Guillaume Bossis & Marc Piechaczyk. (2008) Ubiquitin-independent degradation of proteins by the proteasome. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1786:2, pages 153-177.
Crossref
Crossref
Carine Chavey, Marcus Mühlbauer, Carine Bossard, Ariane Freund, Sébastien Durand, Christian Jorgensen, Christian Jobin & Gwendal Lazennec. (2008) Interleukin-8 Expression Is Regulated by Histone Deacetylases through the Nuclear Factor-κB Pathway in Breast Cancer. Molecular Pharmacology 74:5, pages 1359-1366.
Crossref
Crossref
Min-Jung Lee, Yeong Sang Kim, Shivaani Kummar, Giuseppe Giaccone & Jane B Trepel. (2008) Histone deacetylase inhibitors in cancer therapy. Current Opinion in Oncology 20:6, pages 639-649.
Crossref
Crossref
Andrew J. WilsonDo-Sun ByunShannon NasserLucas B. MurrayKanyalakshmi AyyanarDiego ArangoMaria Figueroa, Ari Melnick, Gary D. Kao, Leonard H. AugenlichtJohn M. Mariadason. (2008) HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21. Molecular Biology of the Cell 19:10, pages 4062-4075.
Crossref
Crossref
Giovanna Pescatore, Olaf Kinzel, Barbara Attenni, Ottavia Cecchetti, Fabrizio Fiore, Massimiliano Fonsi, Michael Rowley, Carsten Schultz-Fademrecht, Sergio Serafini, Christian Steink?hler & Philip Jones. (2008) Optimization of a series of potent and selective ketone histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters 18:20, pages 5528-5532.
Crossref
Crossref
Johan Vansteenkiste, Eric Van Cutsem, Herlinde Dumez, Cong Chen, Justin L. Ricker, Sophia S. Randolph & Patrick Schöffski. (2008) Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Investigational New Drugs 26:5, pages 483-488.
Crossref
Crossref
Deborah W. Knapp. (2008) RUNX3 Methylation and the Potential to Predict the Behavior of Bladder Cancer. The Journal of Urology 180:3, pages 806-807.
Crossref
Crossref
Mickaël Thomas, Jonathan Clarhaut, Isabelle Tranoy-Opalinski, Jean-Pierre Gesson, Joëlle Roche & Sébastien Papot. (2008) Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy. Bioorganic & Medicinal Chemistry 16:17, pages 8109-8116.
Crossref
Crossref
David Krige, Lindsey A. Needham, Lindsay J. Bawden, Nicolas Flores, Hannah Farmer, Lauren E.C. Miles, Erica Stone, Juliana Callaghan, Stephen Chandler, Vanessa L. Clark, Patricia Kirwin-Jones, Valérie Legris, Jo Owen, Thakor Patel, Steve Wood, Gary Box, David Laber, Rajesh Odedra, Annette Wright, L. Michael Wood, Suzanne A. Eccles, Elisabeth A. Bone, Andrew Ayscough & Alan H. Drummond. (2008) CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells. Cancer Research 68:16, pages 6669-6679.
Crossref
Crossref
Ailsa J. FrewRalph K. LindemannBen P. MartinChristopher J. P. ClarkeJanelle SharkeyDesiree A. AnthonyKellie-Marie BanksNicole M. HaynesPradnya GangatirkarKym StanleyJessica E. BoldenKazuyoshi Takeda, Hideo Yagita, J. Paul Secrist, Mark J. SmythRicky W. Johnstone. (2008) Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proceedings of the National Academy of Sciences 105:32, pages 11317-11322.
Crossref
Crossref
Denis Mottet & Vincent Castronovo. (2008) Les histones désacétylases. médecine/sciences 24:8-9, pages 742-746.
Crossref
Crossref
Leigh Ellis, Yan Pan, Gordon K. Smyth, Daniel J. George, Chris McCormack, Roxanne Williams-Truax, Monica Mita, Joachim Beck, Howard Burris, Gail Ryan, Peter Atadja, Dale Butterfoss, Margaret Dugan, Kenneth Culver, Ricky W. Johnstone & H. Miles Prince. (2008) Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma. Clinical Cancer Research 14:14, pages 4500-4510.
Crossref
Crossref
Claire Bonfils, Ann Kalita, Marja Dubay, Lillian L. Siu, Michael A. Carducci, Gregory Reid, Robert E. Martell, Jeffrey M. Besterman & Zuomei Li. (2008) Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay. Clinical Cancer Research 14:11, pages 3441-3449.
Crossref
Crossref
Andrea Newbold, Ralph K. Lindemann, Leonie A. Cluse, Kate F. Whitecross, Anthony E. Dear & Ricky W. Johnstone. (2008) Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Molecular Cancer Therapeutics 7:5, pages 1066-1079.
Crossref
Crossref
Philip Jones, Sergio Altamura, Raffaele De Francesco, Odalys Gonzalez Paz, Olaf Kinzel, Giuseppe Mesiti, Edith Monteagudo, Giovanna Pescatore, Michael Rowley, Maria Verdirame & Christian Steinkühler. (2008) A Novel Series of Potent and Selective Ketone Histone Deacetylase Inhibitors with Antitumor Activity in Vivo. Journal of Medicinal Chemistry 51:8, pages 2350-2353.
Crossref
Crossref
Ferah Yildirim, Karen Gertz, Golo Kronenberg, Christoph Harms, Klaus B. Fink, Andreas Meisel & Matthias Endres. (2008) Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Experimental Neurology 210:2, pages 531-542.
Crossref
Crossref
Regina Fink-Puches & Lorenzo Cerroni. (2008) Cutaneous T-cell lymphoma and emerging therapies. Drug Discovery Today: Disease Mechanisms 5:1, pages e69-e79.
Crossref
Crossref
Beom Soo Shin, Deok Ki Hong, Jong Hwan Kwak, John Kim & Sun Dong Yoo. (2007) LC-MS-MS Determination of Cyclo{(2S)-2-amino-8-[(aminocarbonyl)hydrazono] decanoyl-1-l-tryptophyl-l-isoleucyl-(2R)-2-piperidinecarbonyl} a Novel Histone Deacetylase Inhibitor in Rat Serum. Chromatographia 67:3-4, pages 231-235.
Crossref
Crossref
Nagma KhanMichael JeffersSampath KumarCraig HackettFerenc BoldogNicholai KhramtsovXiaozhong QianEvan MillsStanny C. BerghsNessa CareyPaul W. FinnLaura S. CollinsAnthony TumberJames W. RitchiePeter Buhl Jensen, Henri S. LichensteinMaxwell Sehested. (2007) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochemical Journal 409:2, pages 581-589.
Crossref
Crossref
Li-Ning Xu, Xin Wang & Sheng-Quan Zou. (2008) Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines. World Journal of Gastroenterology 14:16, pages 2578.
Crossref
Crossref
Matthias Körner & Ulrich Tibes. 2008. Progress in Medicinal Chemistry Volume 46. Progress in Medicinal Chemistry Volume 46
205
280
.
Titilope A. Ishola & Dai H. Chung. (2007) Neuroblastoma. Surgical Oncology 16:3, pages 149-156.
Crossref
Crossref
Milos Dokmanovic, Cathy Clarke & Paul A. Marks. (2007) Histone Deacetylase Inhibitors: Overview and Perspectives. Molecular Cancer Research 5:10, pages 981-989.
Crossref
Crossref
X-J Yang & E Seto. (2007) HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26:37, pages 5310-5318.
Crossref
Crossref